Table 1 PARP inhibitors currently in clinical trials
Agent | Route | Phase of development | Comments |
|---|---|---|---|
ABT-888 | Oral | Phase 2 | Being tested in combination with TMZ for patients with metastatic breast cancer and metastatic melanoma |
AG014699 | Intravenous | Phase 2 | Being tested in locally advanced or metastatic BRCA-associated breast or ovarian cancer |
AZD2281 (olaparib) | Oral | Phase 2 | Being tested in multiple phase 2 trials for BRCA-associated advanced breast cancer and ovarian cancer |
BSI-201 | Intravenous | Phase 2 | Being tested in neoadjuvant setting in combination with gemcitabine plus carboplatin for patients with triple-negative breast cancer |
CEP-9722 | Subcutaneous | Phase 1 | Being tested as a single agent and in combination with TMZ in patients with advanced solid tumors |
INO-1001 | Intravenous | Phase 1B | Recently completed phase 1B trial in combination with TMZ for patients with stage III or IV melanoma |
MK4827 | Oral | Phase 1 | Being tested in phase 1 for patients with advanced solid tumors |